[OncoHost in PR Newswire] OncoHost study offers new insights into resistance mechanisms in immunotherapy-treated lung cancer patients

---

BINYAMINA, Israel and CARY, N.C., May 30, 2025 /PRNewswire/ — OncoHost, a technology company transforming the approach to precision oncology through proteomics and AI, today announced the publication of a new study in the Journal for ImmunoTherapy of Cancer (JITC), titled “Decoding Resistance to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Comprehensive Analysis of Plasma Proteomics and Therapeutic Implications.“